TY - JOUR
TI - The complex SNP and CNV genetic architecture of the increased risk of congenital heart defects in Down syndrome
AU - Sailani, M.R.
AU - Makrythanasis, P.
AU - Valsesia, A.
AU - Santoni, F.A.
AU - Deutsch, S.
AU - Popadin, K.
AU - Borel, C.
AU - Migliavacca, E.
AU - Sharp, A.J.
AU - Sail, G.D.
AU - Falconnet, E.
AU - Rabionet, K.
AU - Serra-Juhé, C.
AU - Vicari, S.
AU - Laux, D.
AU - Grattau, Y.
AU - Dembour, G.
AU - Megarbane, A.
AU - Touraine, R.
AU - Stora, S.
AU - Kitsiou, S.
AU - Fryssira, H.
AU - Chatzisevastou-Loukidou, C.
AU - Kanavakis, E.
AU - Merla, G.
AU - Bonnet, D.
AU - Pérez-Jurado, L.A.
AU - Estivill, X.
AU - Delabar, J.M.
AU - Antonarakis, S.E.
JO - Cytogenetic and Genome Research
PY - 2013
VL - 23
TODO - 9
SP - 1410-1421
PB - 
SN - 1424-8581
TODO - 10.1101/gr.147991.112
TODO - messenger RNA;  Smad2 protein;  transcription factor GATA 4, allele;  article;  chromosome 21;  congenital heart malformation;  copy number variation;  diploidy;  Down syndrome;  environmental factor;  exon;  gene expression;  genetic association;  genetic variability;  priority journal;  replication study;  risk assessment;  single nucleotide polymorphism, Case-Control Studies;  Chromosomes, Human, Pair 21;  DNA Copy Number Variations;  DNA-Binding Proteins;  Down Syndrome;  Genetic Predisposition to Disease;  Genome-Wide Association Study;  Heart Defects, Congenital;  Humans;  Polymorphism, Single Nucleotide;  Receptor-Interacting Protein Serine-Threonine Kinases;  Transcription Factors
TODO - Congenital heart defect (CHD) occurs in 40% of Down syndrome (DS) cases. While carrying three copies of chromosome 21 increases the risk for CHD, trisomy 21 itself is not sufficient to cause CHD. Thus, additional genetic variation and/or environmental factors could contribute to the CHD risk. Here we report genomic variations that in oncert with trisomy 21, determine the risk for CHD in DS. This case-control GWAS includes 187 DS with CHD (AVSD = 69, ASD = 53, VSD = 65) as cases, and 151 DS without CHD as controls. Chromosome 21-specific association studies revealed rs2832616 and rs1943950 as CHD risk alleles (adjusted genotypic P-values < 0.05). These signals were confirmed in a replication cohort of 92 DS-CHD cases and 80 DS-without CHD (nominal P-value 0.0022). Furthermore, CNV analyses using a customized chromosome 21 aCGH of 135K probes in 55 DS-AVSD and 53 DS-without CHD revealed three CNV regions associated with AVSD risk (FDR ≤ 0.05). Two of these regions that are located within the previously identified CHD region on chromosome 21 were further confirmed in a replication study of 49 DS-AVSD and 45 DS- without CHD (FDR ≤ 0.05). One of these CNVs maps near the RIPK4 gene, and the second includes the ZBTB21 (previously ZNF295) gene, highlighting the potential role of these genes in the pathogenesis of CHD in DS. We propose that the genetic architecture of the CHD risk of DS is complex and includes trisomy 21, and SNP and CNV variations in chromosome 21. In addition, a yetunidentified genetic variation in the rest of the genome may contribute to this complex genetic architecture. © 2013, Published by Cold Spring Harbor Laboratory Press.
ER -